Phase I/II study of docetaxel/CDGP/5-FU for advanced or recurrent esophageal cancer

Phase I/II study of docetaxel/CDGP/5-FU for advanced or recurrent esophageal cancer - Phase I/II study of DNF for advanced or recurrent esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014462

Enrollment

Registered

2014-07-02

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Chemotherapy of docetaxel, nedaplatin and 5-fluorouracil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) histologically proven esophageal cancer (2) clinical stage IV b (UICC-TMN) or recurrenced case (3) age 20; 80 years (4) an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. (5) adequate baseline bone marrow function, adequate hepatic function adequate renal function, adequate respiratory and cardiac function. (6) a life expectancy of at least 3 months. (7) Written informed consent was obtained from all patients.

Exclusion criteria

Exclusion criteria: (1) history of drug hypersensitivity. (2) active concomitant malignancy. (3) serious complications (severe heart disease, active infection) (4) pregnant or lactating females. (5) The investigator considers not suitable for the study.

Design outcomes

Primary

Measure	Time frame
Phase I To determine the recommended dose (RD) Phase II Safety, Tumor responses	—

Countries

Japan

Contacts

Public ContactYasushi Sato

Tokushima University Graduate School of Biomedical Sciences Department of Community Medicine for Gastroenterology and Oncology

sato.yasushi@tokushima-u.ac.jp+81-88-633-7122

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026